Low Baseline Plasma L-Glutamine Concentration Identifies Hepatocellular Carcinoma Patients at High Risk of Developing Early Gastrointestinal Adverse Events during Sorafenib Treatment
Authors:
- Loreto BoixLBLoreto Boix
- Víctor SapenaVSVíctor Sapena
- Esther SamperESEsther Samper
- Álvaro Díaz-GonzálezÁDÁlvaro Díaz-González
- Neus LlarchNLNeus Llarch
- Gemma IserteGIGemma Iserte
- Leonardo G. Da FonsecaLFLeonardo G. Da Fonseca
- Marco Sanduzzi-ZamparelliMSMarco Sanduzzi-Zamparelli
- Alejandro FornerAFAlejandro Forner
- Jordi BruixJBJordi Bruix
- María ReigMaría Reig
Open Access
- 18 July 2022
- journal article
- research article
- Published by MDPI AG in Gastrointestinal Disorders
- Vol. 4 (3) , 141-152
Abstract
Gastrointestinal adverse events (GIAEs) are common in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. Diarrhea is a prevalent event responsible for treatment interruptions and dosage modifications. Our study evaluates the role of baseline blood L-glutamine (L-Gln) levels in the prediction of gastrointestinal adverse events development early during treatment (eGIAE). Blood L-Gln was measured in 135 patients with advanced HCC prior to starting sorafenib. Any adverse events developed during therapy were registered in a prospective database. We used Mann–Whitney U and Fisher’s exact tests to compare quantitative or categorical variables, respectively, Kaplan–Meier method to analyze time to event variables, log-rank test for the survival functions and Cox regression models to estimate hazard ratios (HR). Fifteen per cent of patients developed eGIAE, with diarrhea as the most frequent one. Patients displaying the lowest L-Gln levels presented a significant higher risk of eGIAE, while those with the highest levels were protected from eGIAE and achieved better survival. Our study shows for the first time the association of baseline blood L-Gln levels with eGIAE development in HCC patients during sorafenib treatment. Low L-Gln concentrations might reflect a potentially compromised intestinal barrier that becomes clinically relevant early after treatment start.Keywords
Funding Information
- Centro de Investigaciones Biomédicas En Red de Enfermedades Hepáticas y Digestivas (CIBERehd) (PI18/00768)
- Instituto de Salud Carlos III (PI18/00768)
This publication has 33 references indexed in Scilit:
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Intestinal and hepatic metabolism of glutamine and citrulline in humansThe Journal of Physiology, 2007
- Glutamine metabolism and signaling in the liverFrontiers in Bioscience-Landmark, 2007
- Intestinal tract injury by drugs: Importance of metabolite delivery by yellow bile roadPharmacology & Therapeutics, 2006
- Alterations in intestinal permeabilityGut, 2006
- l-Glutamine ameliorates acetaldehyde-induced increase in paracellular permeability in Caco-2 cell monolayerAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2004
- Signalling to and from tight junctionsNature Reviews Molecular Cell Biology, 2003
- Ammonia and glutamine metabolism in human liver slices: new aspects on the pathogenesis of hyperammonaemia in chronic liver diseaseEuropean Journal of Clinical Investigation, 1988
- Plasma amino acid patterns in hepatocellular carcinomaBiochemical Medicine and Metabolic Biology, 1987
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958